Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Celyad SA    CYAD   BE0974260896

CELYAD SA

(CYAD)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
07/07/2020 07/08/2020 07/09/2020 07/10/2020 07/13/2020 Date
9.04(c) 9.12(c) 8.72(c) 8.37(c) 8.87 Last
11 912 27 052 49 488 62 929 8 515 Volume
-2.27% +0.88% -4.39% -4.01% +5.97% Change
More quotes
Financials
Sales 2020 3,39 M 3,84 M 3,84 M
Net income 2020 -31,0 M -35,1 M -35,1 M
Net cash position 2020 2,80 M 3,17 M 3,17 M
P/E ratio 2020 -3,40x
Yield 2020 -
Sales 2021 5,76 M 6,52 M 6,52 M
Net income 2021 -34,4 M -39,0 M -39,0 M
Net Debt 2021 32,1 M 36,4 M 36,4 M
P/E ratio 2021 -3,74x
Yield 2021 -
Capitalization 117 M 132 M 132 M
EV / Sales 2020 33,6x
EV / Sales 2021 25,8x
Nbr of Employees 106
Free-Float 83,5%
More Financials
Company
Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies. Celyad utilizes its expertise in cell engineering to target cancer. Celyad's CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. Its lead oncology candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a single dose escalation Phase I clinical trial to... 
More about the company
Latest news on CELYAD SA
06/12CELYAD : Shareholders Approve Rebranding as Celyad Oncology
PU
06/12CELYAD : Oncology Provides Update on Allogeneic CAR-T Franchise including CYAD-1..
PU
06/10CELYAD : - Celyad : Provides Update on Allogeneic CAR-T Franchise including CYAD..
AQ
06/10CELYAD : - Celyad : Rebrands as Celyad : Oncology
AQ
05/07CELYAD : - Celyad : Announces First Quarter 2020 Financial Results and Recent Bu..
AQ
05/07CELYAD SA : 1st quarter results
CO
05/05CELYAD SA : Proxy Statments
CO
04/30CELYAD : - Celyad : to Present Update from CYAD-101 for Advanced Colorectal Canc..
AQ
04/30CELYAD : - Celyad : to Host Remote 2020 Ordinary General Meeting
AQ
04/03CELYAD SA : Mixed general shareholder meeting
CO
03/25CELYAD : - Celyad : Reports Full Year 2019 Financial Results and Provides Busine..
AQ
03/24CELYAD : Reports Full Year 2019 Financial Results and Provides Business Update
PU
03/24CELYAD SA : SEC Filing 6K-4
CO
03/24CELYAD SA : Annual results
CO
03/02CELYAD : Appoints Stephen Rubino as Chief Business Officer
AQ
More news
News in other languages on CELYAD SA
06/25AVIS D'ANALYSTES DU JOUR : Accor, Adyen, Bayer, Iberdrola, Pandora, Siltronic, S..
06/24AVIS D'ANALYSTES DU JOUR : Air France KLM, AMS, Delivery Hero, Evotec, L'Oréal, ..
06/12CELYAD : Shareholders Approve Rebranding as Celyad Oncology
06/12CELYAD : Oncology Provides Update on Allogeneic CAR-T Franchise including CYAD-1..
06/10CELYAD : - Celyad : Provides Update on Allogeneic CAR-T Franchise including CYAD..
More news
Chart CELYAD SA
Duration : Period :
Celyad SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD SA
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 17,73 €
Last Close Price 8,37 €
Spread / Highest target 115%
Spread / Average Target 112%
Spread / Lowest Target 105%
EPS Revisions
Managers
NameTitle
Filippo Joseph Petti Chief Executive Officer & Director
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Serge Goblet Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
CELYAD SA-13.71%132
LONZA GROUP52.43%42 546
CELLTRION, INC.79.28%36 149
SEATTLE GENETICS, INC.52.59%30 180
IQVIA HOLDINGS INC.-7.66%27 247
MODERNA, INC.220.09%24 344